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Abstract: High-dose alcohol misuse induces multiple noxious cardiac effects, including myocyte
hypertrophy and necrosis, interstitial fibrosis, decreased ventricular contraction and ventricle
enlargement. These effects produce diastolic and systolic ventricular dysfunction leading to
congestive heart failure, arrhythmias and an increased death rate. There are multiple, dose-dependent,
synchronic and synergistic mechanisms of alcohol-induced cardiac damage. Ethanol alters membrane
permeability and composition, interferes with receptors and intracellular transients, induces oxidative,
metabolic and energy damage, decreases protein synthesis, excitation-contraction coupling and
increases cell apoptosis. In addition, ethanol decreases myocyte protective and repair mechanisms and
their regeneration. Although there are diverse different strategies to directly target alcohol-induced
heart damage, they are partially effective, and can only be used as support medication in
a multidisciplinary approach. Alcohol abstinence is the preferred goal, but control drinking is useful
in alcohol-addicted subjects not able to abstain. Correction of nutrition, ionic and vitamin deficiencies
and control of alcohol-related systemic organ damage are compulsory. Recently, several growth
factors (myostatin, IGF-1, leptin, ghrelin, miRNA, and ROCK inhibitors) and new cardiomyokines
such as FGF21 have been described to regulate cardiac plasticity and decrease cardiac damage,
improving cardiac repair mechanisms, and they are promising agents in this field. New potential
therapeutic targets aim to control oxidative damage, myocyte hypertrophy, interstitial fibrosis and
persistent apoptosis In addition, stem-cell therapy may improve myocyte regeneration. However,
these strategies are not yet approved for clinical use.
Keywords: alcoholic cardiomyopathy; apoptosis; fibrosis; hypertrophy; regeneration;
cardiomyokines; myostatin; IGF-1; FGF21; miRNA
1. Introduction
Alcohol (Ethanol) consumption is one of the major factors inducing cardiac and vascular diseases
worldwide, mainly when it is consumed at high-dose in binging, unhealthy use high doses or in
unhealthy binge episodes [1–3]. At present, alcohol misuse is a major public health concern due to
the increase in cardiac morbidity and mortality, in addition to damage to the central nervous system
(CNS) and the liver [4]. According to the World Mortality report 2013, cardiovascular diseases
are still the main global cause of death, being responsible for one third of total mortality with
3.3 million deaths in 2012 [5]. Therefore, alcohol is considered as one of the six major contributors to
cardiovascular damage [4,6]. One study reported that the prevalence of alcohol cardiomyopathy in
long-standing alcohol misuse was 13% compared to a matched cohort of non-alcoholics [7]. Although
the possible mechanisms of alcohol-induced cardiovascular damage are not fully understood, studies
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have proposed direct and nutrient-based mechanisms [6–9]. Major therapeutic approaches in this field
involve the avoidance or control of alcohol consumption [10]. However, this is not always possible
since a large quantity of alcohol may be consumed to prevent the withdrawal symptoms in addicts.
In addition, this strategy does not reverse the permanent damage to the heart produced by unhealthy
alcohol consumption [11].
As a plastic organ, the heart is able to partially control and adapt to a damaging toxic agent such as
moderate ethanol consumption [3,12]. However, when this aggression is persistent and at high-doses
over years, it may overcome the protective mechanisms of the heart of the individual, leading to
progressive cardiac damage and ensuing functional dysfunction. Recently, different approaches
have been proposed to reduce alcohol-related heart damage [10–15]. Therefore, a multi-disciplinary
therapeutic approach is needed to increase the protective mechanisms of the heart and thereby improve
public health. The aim of this review is to summarize the new multidisciplinary therapeutic strategies
under development to decrease or reverse alcohol-induced cardiac damage.
2. Mechanism of Alcohol-Induced Cardiac Damage
Ethanol is a highly reactive biologically small-size molecule that easily diffuses through
the biological membranes as well as the intracellular compartments, being able to achieve and
target all intracellular organelles [8,9]. It interacts with membrane phospholipids, ion channels
and receptors, modifying their structure and function, altering intracellular transients as well as
cell energy and oxidative status. It is a potent enzymatic inductor and has active metabolites
(acetaldehyde-acetate, fatty-acid ethyl esthers) [8,16]. Table 1 summarizes the main pathogenic
mechanisms of alcohol-induced heart damage.
Table 1. Mechanisms of alcohol-induced heart damage.
Mechanisms Effectors
Interference with cell signaling and calcium
transients [16,17] MAPK, TGF-β, PKC, PPARγ, MMPs, NF-κβ, PAI-1
Decrease in excitation-contraction coupling
mechanisms [17–19] intracellular [Ca]
2+ transients, L-type Ca2+ channel
Induction of oxidative damage [20,21] ROS, SOD, acetaldehyde
Pro-inflammatory effect [22] IL-2, TNF-α, NF-κβ
Induction of apoptosis [23,24] FAS, TNF-α, TGF-β, Bax-Bcl-2, caspases 3,6




Disruption in protein synthesis [27] decrease in ribosomal protein synthesis, actin, myosin,troponin, titin
Increased glycogen deposition [28,29] glycogen synthase kinase-3β, PARP
Renin-angiotensin-aldosterone activation [30] renin, angiotensin, aldosterone, p38 MAPK/Smad
Interference in hormone-growth factors [31,32] myostatin, ghrelin, leptin, IGF-1
Interference in regulatory cardiomyokines [33,34] FGF21
Decrease in myocyte regeneration [35] myostatin, IGF-1
Impairment of extracellular matrix turnover [16] cytoskeletal structure, connexin channel, desmosome contacts
Imbalance between cardiac lesions/repair
mechanisms [9]
cell apoptosis and necrosis increased myocardial fibrosis
decreased myocyte regeneration
In the cardiac cell, alcohol is a sensitizing agent that interferes with cell structures including
intracellular membranes, channels, receptors and DNA. In addition, ethanol alters protein synthesis
and turnover involving the structural cardiac proteins (actin, myosin, troponin, and titin) and induces
alcohol–protein interaction generating adducts and reactive immune complexes producing additional
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inflammatory damage [1,36]. This myocyte damage by ethanol deregulates cardiac energy production,
causing a decrease in the excitation-coupling mechanism that disturbs cardiac contractility. Acute binge
and chronic lifetime cumulated cardiac damage may have additive effects [1]. Therefore, the potential
damage that ethanol may inflict on cardiac myocytes is multi-factorial, intense and persistent [9].
Table 2 summarizes the diverse harmful cardiovascular effects of high-dose alcohol. In general,
alcohol-induced heart damage may involve a myriad of seemingly independently acting molecular
signals that may act synchronically and also synergistically. Age, genetic polymorphisms, gender,
race and behavioral factors can modify the personal susceptibility to this ethanol-induced cardiac
damage [9,16]. Although they are not the main pathologic factors in alcoholic cardiomyopathy (ACM),
alcohol-induced vitamins (thiamine, pyridoxine, and cobalamin), cofactors (folate), protein or caloric
malnutrition, may increase the severity of heart damage [2,9]. Alcohol consumption can also increase
the adverse effects of other cardiac damaging factors causes of heart damage, mainly tobacco and
cocaine [19,37]. Therefore, evaluation of alcohol-induced heart damage should be performed in
a multidisciplinary and personal basis
Table 2. The effects of high-dose alcohol on short and long-term cardiovascular damage.













Atrial dysfunction Arterial hypertension
Arterial hypertension Chronic arrhythmias Peripheral artery disease













Sudden death Coronary heart
disease
Angina
Increased risk of diabetesMyocardial
infarction
Increased cardiovascular mortality Interference with other cardiotoxic drugs(tobacco, cocaine)
3. Strategies to Decrease Factors Inducing Heart Damage
Although many strategies have been suggested to decrease heart damage in general [38–41],
they are only partially effective in cases of alcohol-related heart damage. Thus, they can only be
considered as complementary treatments. The following paragraphs describe important approaches
currently being used to suppress alcohol-induced cardiac disorders.
3.1. Control of Alcohol Consumption
Alcohol-induced cardiac damage is directly associated with binge drinking and chronic non-binge
drinking in which the lifetime cumulated dose of ethanol is a relevant factor [1–3]. Control strategies
may involve both drinking modes [1,13,42]. Development of addiction and withdrawal symptoms
further complicate treatment approaches [10,11]. Binge drinking, defined as the consumption of
more than five alcohol units per occasion, induces an acute decrease of myocyte contractility and
arrhythmia and may cause sudden death [43]. In subjects with previously defined heart disease,
binge drinking may be a serious issue and should be avoided [1,9]. Success in attempting to abstain
from alcohol is only achieved in 40%–50% of long-term alcohol consumers probably due to difficulties
in the management of alcohol withdrawal. The latter is a relevant issue to be addressed in order to
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avoid or decrease persistent alcohol-induced heart damage [11]. Recently, the efficacy of the abstinence
approach was evaluated in patients with alcoholic cardiomyopathy [42]. This study showed that:
(1) subjects who completely abstained from alcohol showed improvement in cardiovascular function
without significant withdrawal symptoms; and (2) those subjects who could not abstain, but were able
to significantly decrease their alcohol consumption in a controlled manner (20–60 g/day) also presented
major improvement in cardiac function [42]. This suggests that ethanol abstention is the preferred
goal in subjects with ACM, although controlled drinking is still a useful strategy in subjects not able
to abstain. Any decrease of the quantity of alcohol consumed may be useful to avoid progressive
alcohol-induced heart damage.
3.2. Comorbid Factors
In addition to alcohol, control of tobacco, cocaine and other unhealthy drug consumption toxic
substances is necessary to manage alcohol addiction in a multi-toxic consumption pattern [44,45].
This approach may require a specialized multidisciplinary strategy with personalized cognitive-behavioral
psychotherapy and the use of pharmacological support for alcohol and drug addiction [13].
3.3. Therapy against Alcohol-Induced Non-Cardiac Systemic Damage
Alcohol is a systemic toxic substance that, in addition to heart damage, induces multiple
simultaneous organ-damage, mainly in the liver, brain, muscle, lung, and kidney, and also disturbs the
nutritional status [9]. Subclinical systemic organ damage has an independent influence on cardiac risk
and may amplify the estimated risk damage [46]. In fact, as previously reported in the literature [47],
it is pivotal to consider systemic organ impairment when approaching patients with heart failure,
mostly when there is a mutual noxae such as alcohol [46]. Subclinical organ damage is a predictor of
cardiovascular death ant its evaluation may improve risk prediction [48]. Similarly, cardiovascular
disorders may also themselves induce systemic organ damage involving lung, liver, kidney, and brain
dysfunction [49].
The liver is the most important organ affected by ethanol toxicity and is clearly interrelated
with heart damage because of some common pathogenic injury mechanisms such as oxidative and
inflammatory damage as well as the induction of apoptosis and fibrosis [50]. Uncompensated liver
cirrhosis contributes to alterations in cardiac function and should be controlled [51].
After the liver, the brain is the organ most frequently involved in systemic alcohol toxicity
causing a wide spectrum of structural and functional changes in addition to alcohol addiction [52].
This produces an important health-related systemic impact [53]. Some alcohol-induced brain diseases
such as intracranial hemorrhage produce myocardial damage and cardiac arrhythmia, probably
through increased catecholamine production (sympathetic storm) that may also increase sudden death
in alcoholism [54]. Due to the known brain-heart health connection, control of the visceral organ
dysfunction that occurs as a result of neurological stimuli (neurological heart disease) is also relevant
to stabilize alcohol-induced heart damage [55].
The lung is also affected by chronic alcohol injury, increasing the risk of pneumonia, sepsis and
acute respiratory distress syndrome (ARDS) [56]. The presence of alcohol-induced lung damage
increases oxidative stress and interferes with heart damage, with a raised incidence of coronary heart
disease [57].
Skeletal muscle is anatomically and functionally similar to the heart, and there is a clear
relationship between cardiac and skeletal damage induced by ethanol [1,28]. In end-stage heart
failure, muscle wasting and sarcopenia are relevant factors influencing the quality of life [58].
Therefore, improvement of muscle thophism and strength contributes to improving heart function in
chronic alcoholics.
The kidney may also be damaged by high-dose ethanol in experimental [59] and clinical [60]
settings. Since kidney dysfunction can cause cardiac overload and increased oxidative stress [61], it is
important to control kidney damage in subjects with alcohol-induced heart damage.
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The presence of sustained systemic inflammatory response also increases alcohol-induced heart
damage [22,27,62], and must be controlled to avoid increased heart-damage.
Caloric and protein malnutrition as well as vitamin deficiencies (i.e., cardiac beriberi)
are frequent in chronic alcoholics [51,63,64] and contribute to an increase in alcohol-induced
structural and functional cardiac changes [1]. Similarly, ionic disruption including hypo- and
hyperkaliemia, hypocalcemia, hypomagnesemia and hyperphosphoremia worsens cardiac contractility
and excitability [1,64]. Therefore any additional nutrition, vitamin or ion disturbance should be
corrected to stabilize alcohol-mediated heart damage [1,7,9].
Thus, inclusion of systemic organ damage markers in the assessment of alcohol-induced heart
damage and control of non-cardiac systemic damage may contribute to improve alcohol-induced
heart damage.
3.4. Therapeutic Approaches against Myocyte Hypertrophy and Cell Loss
Cardiac hypertrophy increases cardiomyocyte size and myocardial mass in response to
physiological or pathological events that also induce remodeling [65]. Myocyte hypertrophy is
a key factor in the transition from a normal to a pathologic heart in alcohol-induced and other
causes of heart damage [28,66]. However, cardiac hypertrophy may also be an adaptive mechanism
to stressful conditions of the heart, but prolonged hypertrophy may lead to cardiac dysfunction
and heart failure which represents the primary cause of human morbidity and mortality [65,67].
According to the Frank–Starling law, mechanical overload to the ventricle is compensated with
chamber enlargement [66,68]. This process is also accompanied by concentric hypertrophy that may
progress to outflow obstruction [67]. In the case of alcohol, ventricular enlargement is eccentric,
with preservation of septum thickness, thus avoiding blood-flow obstruction [3,29].
Factors associated with pathological myocyte hypertrophy and abnormal remodeling are
cytokine-mediated inflammation, disruption of intracellular transduction signals, angiogenesis and
interactions with other cells mediated by the autonomic system [66,69]. In addition, epigenetic factors
may also modulate this process [67]. Myocyte loss by necrosis or apoptosis is a relevant mechanism
in cardiac dysfunction and is present in major heart diseases [70]. High-dose alcohol consumption
has clearly shown to increase cardiac apoptosis pathways in animal [23] and human studies [24].
Thus, pro-apoptotic mechanisms are activated in alcoholic patients without heart damage. Chronic
alcoholic subjects with structural heart damage showed higher apoptotic indexes in deoxyribonucleotidyl
transferase-mediated dUTP-biotin nick end-labeling, Bax, and Bcl-2 assays as compared with control
subjects [23,24]. Since the control of myocyte apoptosis is a key factor in alcohol-induced heart damage [9],
the most relevant strategies to control cardiac hypertrophy and myocyte loss include the following.
3.4.1. Myostatin (Mstn)
Mstn regulation has been proposed to control excessive myocyte hypertrophy. Mstn is the growth
and differentiation factor 8 (GDF-8), a member of the transforming growth factor-β superfamily
of growth factors which acts as the negative regulator of skeletal muscle and cardiac growth [71].
Mstn activity protects cardiac cells from apoptosis [72]. However, Mstn has other cardiac effects,
increasing hypertrophy and also inhibiting myocyte proliferation. In fact, Mstn represses AMPK
activation of TAK1, restricting hypertrophy and regulating cardiac metabolism interacting with key
metabolic enzymes [73]. Adult- versus embryonic-specific inactivation of Mstn has a different effect.
In adults, Mstn inactivation induces excessive expression in non-cardiomyocytes in the heart and rescues
hypertrophy in aging mice, confirming the role of Mstn in the regulation of cardiac hypertrophy [74].
Therefore, Mstn, as well as its analog GDF11, have anti-hypertrophic and cardio-protective mechanisms,
necessary to maintain aerobic energy metabolism in adult cardiomyocytes [75].
Earlier experimental animal studies have shown a significant increase in cardiac Mstn expression
in chronic high-dose alcohol exposure when compared to non-exposed controls, confirming a clear
over-expression of Mstn with alcohol consumption [67,76]. This is further confirmed by the observation
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that, in subjects with alcohol-induced cardiomyopathy, there a significant increase in cardiac Mstn
expression in comparison to healthy controls [31]. This Mstn up-regulation has been observed either
in alcoholic, hypertensive, valves, ischemic or idiopathic cardiomyopathy (CMP), being independent
of the etiologic origin of the CMP [31,77].
To explain the relationship between Mstn and cardiac hypertrophy we should consider that
Mstn represses AMPK and interacts with key metabolic proteins and enzymes [78]. Therefore,
Mstn up-regulation may be a regulatory mechanism activated to avoid excessive hypertrophy and
pathological cardiac remodeling in ethanol-induced cardiac damage [73].
3.4.2. Adrenergic Receptors (AR)
Cardiac hypertrophy is regulated by multiple factors with a clear influence of α1-AR. Indeed,
the signaling events of this receptor contribute to the definition of molecular and cellular cardiac
features [65,79]. New hypotheses have emerged concerning the functional role of α1-AR receptors
in the heart. Regulation of these receptors may modify cardiac hypertrophy [65]. Thus, endogenous
BNP attenuates cardiomyocyte hypertrophy induced by Ang II via the p38 MAPK/Smad signaling
pathway [80,81]. Overstimulation of the Renin-Angiotensin System (RAS) has been implicated in
a chain of events that contribute to the pathogenesis of cardiovascular disease and cardiac remodeling.
Novel pathways within the RAS and new therapeutic approaches that target this system are required
to further reduce Ang II formation, and thereby provide patients with additional benefits from a more
complete blockade of the RAS [82]. In addition, leptin antagonist therapy may attenuate angiotensin
II-induced LV hypertrophy and has been used in local application [83]. β-3 AR also exerts antioxidant
protective effects, improving cardiac hypertrophy and remodeling in response to neuro-hormonal
stimulation [84].
3.4.3. Oxidative/Nitrative Stress
Oxidative/Nitrative stress, a key etiological factor in the development of alcohol-induced
cardiac toxicity [20], is related to mitochondrial function, myocyte hypertrophy, autophagy and
apoptosis [79,85]. Reducing oxidative stress may also contribute to decreasing myocyte hypertrophy
as described with the use of the non-peptide angiotensin-(1-7) analogous AVE 0991. In fact, AVE 0991
significantly down-regulates the mean diameter of myocytes, inhibits NOX2 and NOX4 expression
and attenuates gene expression of the hypertrophic markers. AVE 0991 treatment could attenuate
cardiac hypertrophy and improve heart function, which may be due to reduce oxidative stress [86].
Therefore, treatments addressed at reducing heart oxidative stress may be a useful complementary
approach to consider in order to reduce unhealthy cardiac hypertrophy.
Epigallocatechin gallate (EGCG) is a polyphenol derived from green tea. It has a wide range of
biological activities, including antioxidant and anti-apoptotic activities though the PI3K/Akt signaling
pathway. EGCG post-conditioning inhibits myocardial apoptosis and restores the autophagic flux,
suggesting that it may be useful as an anti-apoptotic cardioprotective agent [87].
3.4.4. Myocardium RhoA/ROCK Pathway
The Rho-associated coiled-coil containing kinases (ROCKs) are members of the serine/threonine
protein kinase family, which mediates the downstream effects of the small GTP-binding protein
RhoA [88]. These pathways contribute to cardiac remodeling induced by persistent hypertrophic stress,
leading to heart dysfunction and failure. As evidenced in experimental studies, the use of RhoA/ROCK
inhibitors is a potential cardiac target to avoid hypertrophy [89]. Stretch-induced activation of RhoA
differentially regulates angiotensinogen gene expression by modulating p38 and JNK activation [90].
RhoA/ROCK also regulates an apoptotic response depending on the cell type and the apoptotic
stimulus. Acute RhoA/ROCK activation inhibits apoptosis through the FAK/PI3K/Akt survival
pathway. Conversely, more sustained activation of Rho/ROCK (48–72 h) induces apoptosis through
activation of p53/Bax-mediated mitochondrial death pathway. The anti-apoptotic effects of ROCK1
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deletion were found to be associated with enhanced ERK/MAPK and/or Akt activation. This suggests
a role for ROCK1 in modulating the activity of these survival pathways under pathological conditions
that may contribute to cardiac remodeling [89].
Studies have shown that Azaindole-1, a novel RhoA/ROCK ATP-competitive inhibitor, has blood
pressure lowering effects [91]. SLx-2119 and Fasudil competitively bind to the ROCK ATP pocket [92].
These inhibitors block the generation of inflammatory cytokines, such as interleukin-6 and tumor
necrosis factor-alpha and induce vasorelaxation. Fasudil is the only ROCK inhibitor approved for
human use for the prevention and treatment of cerebral vasospasm. Given the safety and effectiveness
and extensive preclinical data described in experimental model systems, small clinical trials have
been carried out and have demonstrated some of the benefits of fasudil in cardiac hypertrophy [88,92].
The future development and application of isoform-specific ROCK inhibitors in knockout animal
models as well as human clinical trials are expected [89].
3.4.5. Sirtuins
Sirtuins are the Sir2A family of class III histone deacetylases [93] that have recently been involved
in a wide range of physiological and pathological processes, including aging, energy regulation,
as well as cardiac hypertrophy, apoptosis and inflammation. Specifically, Sirt7 is known to regulate
heart apoptosis and stress responses [94]. Sirt3 protects cardiomyocytes from oxidative stress and
suppresses cardiac hypertrophy [94]. Sirt1, Sirt3 and Sirt6 have also demonstrated to attenuate cardiac
hypertrophy, and protect cardiomyocytes from aging and oxidative stress [94,95]. Resveratrol is
a natural Sirt-1-specific activator that also exerts cardio-protective effects that regulate redox signaling
during oxidative stress in cardiovascular disease. Resveratrol-regulated autophagy may play a role in
degrading damaged organelles, thus improving cardiac function [96]. The administration of resveratrol
prevents the alteration in SIRT-1 in type-2 diabetes mellitus and SIRT-1, 2, 3 and SIRT-5 in the type 1
diabetes mellitus rat heart [97].
3.4.6. Caspase Inhibition
Since caspases are pro-apoptotic mitochondrial inductors, inhibition of caspase 3 activity has
been proposed as an anti-apoptotic treatment. Hesperetin a flavonone glycoside has been proposed to
attenuate mitochondria-dependent cardiac apoptosis [98].
3.4.7. Suppressor of IKKε (SIKE)
Another potential mechanism to treat cardiac hypertrophy, remodeling and heart failure is
inhibition of the TBK1/AKT pathway. SIKE, a suppressor of IKKε, produces negative regulation of
the interferon pathway and regulates cardiac remodeling [99]. Sike-deficient mice develop cardiac
hypertrophy, whereas sike-overexpressing transgenic (Sike-TG) mice are protected from hypertrophic
stimuli. Due to its inhibitory regulation of the TBK1/AKT axis, SIKE has been proposed as a negative
regulator of cardiac remodeling in multiple animal species, and may represent a therapeutic target for
the treatment of cardiac hypertrophy and heart failure [99].
3.4.8. Micro RNA (miRNAs)
miRNAs are non-coding RNAs containing 18–25 nucleotides different from other RNAs [100,101].
mRNAs are involved in the regulation of oxidative stress-induced apoptosis [102]. They play
essential roles in modulating gene expression and are involved in several cardiovascular disorders
including cardiac hypertrophy [101–103]. Selected miRNA have regulatory effects on target gene
expression. Thus, miR-34 family (miR-34a, -34b, and -34c) expression is up-regulated in different
heart diseases. miR-153 regulates the survival of cardiomyocytes during oxidative stress through the
modulation of apoptosis and autophagy directly mediated by targeting Mcl-1. This demonstrates
the potential therapeutic role of miR-153 in the control of heart apoptosis [104]. Inhibition with
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antimiR-34a/antimiR-34 has also emerged as a promising therapeutic strategy with implications for
cardiac drug development addressed to control heart hypertrophy and heart failure [103,105].
3.4.9. G-Protein Signaling Pathway
G-proteins are part of is a multi-domain system that regulates signaling pathways with a pivotal
role influencing pathologic cardiac hypertrophy and remodeling [106]. G-protein-mediated activation
of MEK1/2-ERK1/2 signaling may be responsible for the pro-hypertrophic action of the regulator of
G-protein signaling (RGS). RGS12 is a multi-domain member of the RGS family and plays a regulatory
role in various signaling pathways, although the precise effect of RGS12 on cardiac hypertrophy
remains largely unknown [107]. Therefore, regulation of G-protein pathways in cardiac hypertrophy
through inhibition of RGS-10 [107] or RGHS6 [108] have been proposed as potential therapeutic targets
to attenuate pressure overload-driven cardiac remodeling.
3.4.10. Fibroblast Growth-Factor 21 (FGF21)
Experimental in vivo and in vitro studies in mice have shown that FGF-21 protects against cardiac
hypertrophy. FGF21(−/−) mice exhibit enhanced induction of cardiac hypertrophy markers and
pro-inflammatory pathways [33]. Furthermore, FGF21 is induced in failing human hearts [34] but
human trials with FGF-21 have not yet been performed to actually demonstrate the protective role of
FGF21 in heart diseases.
3.4.11. Peroxisome Proliferator Activated Receptor Agonists (PPAR)
PPARs may protect against cardiac hypertrophy. PPARα agonists such as fibrates and PPARβ/δ
agonists exert potent anti-hypertrophic and anti-inflammatory effects on the heart [109]. Pioglitazone,
a peroxisome proliferator activated receptor (PPARγ) agonist protects against cardiac hypertrophy by
inhibiting AKT/GSK3β and MAPK signaling pathways [110].
3.4.12. Resveratrol
A natural plant product, also known as stilbenoid, selectively inhibits pathological cardiac
signaling pathways and differentially regulates pathological cardiac hypertrophy [111]. Resveratrol
inhibits NFAT-dependent transcription. The effects of low concentrations of resveratrol are
AMPK-independent. According to these effects, resveratrol may be used in the complementary
treatment of pathological cardiac hypertrophy.
3.4.13. Alpha-Lipoic Acid (ALA)
ALA has been described as a therapeutic agent for a number of conditions related to cardiovascular
disease [112]. ALA has a robust anti-hypertrophic and anti-remodeling effect that is mediated by
inhibition of C/EBPβ activation [113]. Other authors have suggested that ALA partially attenuates
cardiac hypertrophy via inhibition of PPAR2 and subsequent activation of Sirt1 and have proposed
that it may have a potential cardio-protective role [112].
3.4.14. BNIP-3
The Bcl-2/adenovirus E1B 19-kD interacting protein 3 (BNIP3) is a target in inflammation-mediated
heart failure. It decreases heart apoptosis and may subsequently improve heart damage [81].
The strategies mentioned above are not yet available as regular treatments since they have not been
tested in controlled clinical trials. Nonetheless, some of these approaches, such as myostatin, anti-miRNA
and adrenergic receptor regulators, may be close to translation from the laboratory to the clinic.
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3.5. Control of Cardiac Fibrosis
Cardiac fibrosis is the excessive deposition of extracellular matrix (ECM), such as collagens and
fibronectin, resulting in the accumulation of fibrous connective tissue [114–116]. Although fibrosis is
essential in the biological repair process of damaged tissues, heart fibrosis is a pathological process
that may induce stiffening, reduced oxygen diffusion, and is associated with arrhythmias, ventricular
dysfunction and failure leading to pathological remodeling [117].
Replacement of lost cardiomyocytes by fibrotic material makes the environment less favorable,
producing additional cardiomyocyte death. This also generates a vicious cycle of further decline of
cardiac function [117]. This fibrotic process is implicated in almost all forms of heart disease [116].
The cardiac fibroblast is a relevant cell in the homeostasis of the ECM [118]. These cells actively
synthesize connective tissue components and cause organ fibrosis [119]. Upon injury, stimulated,
cardiac fibroblasts transform to a myofibroblast phenotype and develop a process of fibrocyte
differentiation, epithelial to mesenchymal trans-differentiation, and endothelial to mesenchymal
transition. Many different mediators and signaling pathways influence cardiac fibroblast function such
as transforming growth factor beta (TGF-β), angiotensin II and platelet-derived growth factor (PDGF).
Inhibition of the myofibroblast activation process may be useful to prevent cardiac fibrosis, including
the use of these candidate proteins as treatment targets and the prospect of anti-fibrotic therapy either
by systemic or localized delivery [120,121]. Breaking this fibrosis-cell death axis could further halt
pathological cardiac regression and potentially reverse remodeling [117].
Ethanol is a direct highly active pro-fibrogenic molecule [25]. In addition to its direct effect,
acetaldehyde adducts and lipid peroxidation products generated by ethanol metabolism also have
pro-fibrogenic actions. Similar to that happens in the liver and pancreas, cardiac fibrosis is a relevant
process in alcoholic cardiomyopathy, being present in both subendocardial and interstitial spaces
usually in advanced stages of disease [28].
Despite the critical importance of fibrosis in cardiovascular disease, our limited understanding
of the physiopathology of cardiac fibroblasts impedes the development of potential therapies that
effectively target this cell type and its pathological contribution to disease progression [114,116].
Some mechanisms proposed to decrease fibrotic cardiac formation also share a similar influence on
myocyte hypertrophy and cell loss, with the following being the most relevant:
3.5.1. ROCK Inhibitors
In addition to the previously mentioned role on cardiac hypertrophy, ROCK inhibitors, such as
fasudil contribute to controlling cardiac fibrosis and subsequent cardiac remodeling and heart
failure [88,89]. However, there have been no human studies to corroborate this anti-fibrogenic role.
3.5.2. miRNA
In relation to cardiac fibrosis, miR-21 and miR-29 are the agents most intensively studied.
The miR-29 family is down-regulated in failing hearts and has been associated with several
ECM-mediating encoding genes for fibrillin, elastin, and collagens under TGF-β regulation.
miRNA have been proposed as biomarkers as well as targets for therapy [105].
3.5.3. TGF-β Antagonists
TGF-β antagonism inhibits myocardial fibrosis by neutralizing anti-TGF-β antibodies or by
proteoglycans and prevents the increase in gene expression of ECM proteins. This suggests a TGF-β
mediated role in ECM protein production and fibrosis [121,122].
3.5.4. Cytokines and Chemokines
In addition to TGF-β, several cytokines, chemokines, and growth factors are induced in the
injured heart and may contribute to myofibroblast differentiation. Thus, endothelin-1, angiotensin II
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(Ang II), connective tissue growth factor (CCN2/CTGF), plateled-derived growth-factor (PDGF),
serum response factor (SRF), transient receptor potential (TRP) channels, and mitogen-activated
protein kinases (MAPKs) appear to act in a network that contributes to myofibroblast differentiation
and persistence [118]. The chemokine Interferon-γ inducible Protein (IP)-10 exerts anti-fibrotic actions,
inhibiting fibroblast migration [123]. Drugs targeting these proteins are currently under consideration
as anti-fibrotic treatments [121].
3.5.5. Relaxin
Relaxin is a cardioprotective agent that is up-regulated in heart disease. Relaxin may protect the
heart via its anti-hypertrophic, anti-inflammatory, vasodilator and anti-fibrotic actions. This agent
is an effective anti-fibrotic agent due to its specific ability to inhibit pro-fibrotic cytokine and/or
growth factor-mediated fibroblast proliferation, differentiation and matrix production. It is able to
down-regulate tissue inhibitor of metalloproteinase activity. Relaxin has been used in the treatment of
non-systolic heart failure [124,125].
3.5.6. Myostatin (Mstn).
Mstn induces interstitial fibrosis in the heart via TAK1 and p38. Therefore, Mstn inhibition may
potentially protect against cardiac fibrosis [126].
3.5.7. ω-3 Polyunsaturated Fatty Acids (ω-3 PUFAs)
Recent studies suggest thatω-3 polyunsaturated fatty acids (ω-3 PUFAs) inhibit cardiac fibrosis
and attenuate diastolic dysfunction. This opens up possible new avenues for treatment of diastolic
heart failure through the inhibition of cardiac fibrosis [127].
3.5.8. Pioglitazone
Pioglitazone, a PPARγ activator has been reported to suppress cardiac fibrosis inhibiting the
AKT/GSK3β and MAPK signaling pathways [110].
3.5.9. Anthrocyanin
Purple rice anthocyanin extract may improve cardiac function by inhibiting cardiac hypertrophy
and fibrosis [128].
3.6. Control of Oxidative-Energy Damage
Oxidative pathways are one of the central mechanisms of the development of heart disease [79].
Chronic alcohol consumption disturbs heart mitochondrial function and oxidative status [20], resulting
in an increase in ROS [21,129] (Figure 1). It may also increase the overexpression of anti-oxidative
enzymes [130,131] and inhibit the redox-sensitive transcriptional factor (Nrf cascade), decreasing
myocyte proliferation [132]. In a study with chronic alcoholic heart donors, the presence of dilated
CMP was related to an increase in myocardial superoxide dismutase activity, a fact supposed to be
a compensatory mechanism against alcohol-induced oxidative damage [133]. In the healthy heart,
coronary blood flow is linked to the production of metabolites, which modulate smooth muscle
tone in a redox-dependent manner. Some ion channels such as ATP-sensitive potassium (KATP)
channels, voltage-gated potassium (Kv) channels, voltage-gated sodium (Nav) channels, and the
L-Type ryanodine Ca2+ channel, among others, play a critical role in coupling myocardial blood flow
to cardiac metabolism [18,134,135]. In fact, genetic polymorphisms or the absence of these channels
disassociates metabolism from flow, resulting in tissue hypoxia, myocardial ischemia and cardiac pump
dysfunction [134,135]. Thus, it would be interesting to determine whether genetic polymorphisms
encoding for ion channels may be related to a major susceptibility to alcohol-induced myocardial
ischemia and cardiac pump dysfunction [135,136]. Although antioxidant therapy seems indicated
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in alcohol-induced heart damage, clinical evidence of its utility is still low [79]. Some important
approaches are discussed below.
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3.6.1. Novel Cardiomyokines
Myokines are a family of peptides produced, expressed, and released by myocytes [137,138].
They exert autocrine, paracrine or endocrine effects that may modulate the cardiac damage inflicted by
different metabolic or toxic agents. Chemokine synthesis is stimulated by danger signals released from
dying cells and damaged ECM, activating innate immune pathways [123]. Chemokines are involved
in some contra-regulatory pathways, which emerge t modulate t e intensity of cardiac oxidative
damage [139].
Fibroblast growth factor-21 (FGF21) is a mediator of the mitochondrial pathways and has
a relevant role in heart diseases [34]. It regulates ROS, superoxide dismutase-2 production and
gene expression of the encoding proteins involved in anti-oxidative pathways. Considering this
relevant pathophysiologic role, FGF21 has been proposed as a biomarker in mitochondrial damage in
heart failure n heart damag [138]. The role of this emergi g cardiomyokine in the pathogenesis
of alcohol-induced heart damage may be relevant as a contra-regulatory pathway to modulate the
intensity of heart damage [9]. In addition, FGF21 may be considered as a potential diagnostic marker
of heart damage [139]. Therefore, the role of cardiomyokines in ACM oxidative damage is relevant,
but needs further research.
3.6.2. Leptin
Increased plasma leptin levels have been described in chronic alcohol consumption, producing
heart and systemic oxidative damage [140]. Attemp s t control this leptin-mediated oxidative damage
in chronic alcoholics have been made with L-Carniti e an Ascorbic acid, with no clear results.
3.6.3. Pioglitazone
In addition to anti-fibrotic activity, pioglitazone has been suggested to have antioxidant protective
cardiac effects mediated by catalase against oxidative stress [141].
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3.6.4. Ghrelin
The endogenous ligand of growth hormone secretagogue receptor (GHS-R) ghrelin is a metabolic
and energetic extra-hypothalamic regulator. It inhibits endoplasmic reticulum stress (ERS) and
apoptosis and has cardio-protective properties [142]. Therefore, ghrelin could potentially be used to
protect the heart against ERS-induced injury and apoptosis, and its potential therapeutic application
has been suggested [143].
3.6.5. Phenolic Compounds
The natural biphenolic compound Honokiol derived from the bark of magnolia trees has cardiac
anti-oxidative properties with anti-hypertrophic effects due to activation of the deacetylase Sirt3 [144].
Similarly, Leonurus. cardiaca herb extract effectively attenuates the generation of free radicals in
heart mitochondria and has been proposed asa useful remedy to protect cardiac muscles from
oxidative damage [145]. Dietary supplementation with soy isoflavones increases eNOS activity
and expression and activate the Nrf2-Keap1 signaling pathway. This leads to an up-regulation of
detoxifying and antioxidant defensive genes with potential cardiac benefit. However, trials with
isoflavone or phytoestrogens supply have largely reported only marginal health benefits [146].
Since the description of the so-called “French paradox” [147], in which low cardiovascular risk
was related to red-wine consumption compared to other alcoholic beverages, many epidemiological
studies [148,149] have suggested that polyphenols from red wine and other sources, mainly flavonoids,
lignans and hydroxybenzoic acids, are able to decrease the global cardiovascular risk by 46% and of
all-cause death by 37% [150]. However, clinical trials are needed to confirm this effect and establish
specific recommendations [151].
4. Strategies to Improve Cell Regeneration and Repair
The adult heart is a terminal differentiated organ with very low regeneration power [35,152].
Regeneration of the injured myocardium is one of the most ambitious goals in modern cardiology [153].
A potential treatment strategy to improve injured cardiac tissues is enhancement of the endogenous
regenerative capacity [35,153]. Recent reports have suggested that inflammation and different
populations of cardiac macrophages might contribute to regenerative versus fibrotic responses [154].
4.1. Ki-67 and Myostatin
One marker of myocardial proliferation is Ki-67. The percentage of cardiac myocytes expressing
Ki-57 in the nuclear area is an index of cardiac regeneration [155]. This Ki-67 percentage increases in
all-cause cardiac damage as a compensatory response to damage. This is also the case of ACM
in which the Ki-67 index is significantly increased in comparison to alcoholics without cardiac
damage. However, high-doses of alcohol also inhibit myocardial proliferation, probably by Mstn
up-regulation [9]. Thus, in chronic alcoholics the relative increase in Ki-67 percentage is 67% lower
than in subjects with hypertension or other causes of CMP, evidencing a clear decrease in myocyte
proliferation capacity in alcoholics. As a potential treatment target for ACM, Mstn inhibition could
help to stimulate myocyte cell proliferation [156]. However, some limitations to this treatment still
make it difficult to apply since Mstn inhibition produces glycolysis and increased glycogen storage
and cardiac hypertrophy [157].
4.2. Telocytes
Cardiac telocytes support the stem cells for activation and commitment, and also help their
migration toward injured myocardium. Telocyte reduction disturbs intercellular signaling and may
participate in three-dimensional myocardium’s organization. Increasing telocyte function may help
induce myocardial regeneration [158].
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4.3. Stem Cell Therapy
The adult human heart has an extremely limited regenerative capacity, and there is minimal
contribution from local progenitor cells [159]. In ACM, chronic alcohol consumption decreases the
heart myocyte proliferation rate and contributes to decreasing this repair mechanism [35,36,155].
Cell therapy for heart repair has been performed using different cell types including skeletal myocytes,
bone marrow mononuclear cells, mesenchymal stem cells, and cardiac-derived cells [160]. Bone marrow
mononuclear cells for intracoronary cell therapy have been tested in different phase III trials after
myocardial infarction but not in ACM. They showed non-homogeneous and diverse functional
results [159,161]. A European BAMI multi-centric trial on the effect of intracoronary reinfusion of bone
marrow-derived mononuclear cells is ongoing and may provide new data [162]. Mesenchymal stem
cells (MSC), either autologous or allogeneic, have been established as one of the potential therapeutic
agents in cardiac regeneration. They have been used for either revitalizing cardiac stem cells or
revascularizing the arteries and veins of the heart mainly after acute myocardial infarction [163].
Most MSC studies have demonstrated that the cells die off within a week or two after transplantation,
with little direct cardiac differentiation [159].
Recent advances using human stem cell-derived cardiomyocytes have been established as a next
generation of cell type replacement therapy for moving forward. However, certain challenges must be
overcome for this technique to be successful in the clinical practice [159].
Overall, this therapy is able to improve systolic and diastolic ventricle function and decrease
inflammation and fibrosis. These beneficial effects are probably due to the indirect paracrine capacity
of transplanted stem cells to facilitate endogenous cardiac repair processes, having demonstrated
safety and modest efficacy in phase III clinical trials. At present, technical challenges still limit stem cell
use in human studies [164,165], with these challenges including poor definition of the cell types used,
the diversity in cell-handling procedures, and functional variability intrinsic to autologous-derived
cells thus limiting factors of cell-based therapies [160].
4.4. Heart Transplantion
One final possibility to repair end-stage ACM is heart transplantation [166]. However, this is
a limited strategy because chronic alcoholics with end-stage ACM (left-ventricle ejection fraction <15%)
usually have liver cirrhosis, dementia or other systemic organ damage due to alcohol. In addition,
a long period of alcohol abstinence should be guaranteed before heart transplantation. In a series of
94 chronic alcoholics with ACM, over a 59-month follow-up, 15% achieved heart transplantation [2].
5. Conclusions and Future Trends
In alcohol-mediated heart damage, the final result of dysfunction, structural damage and cardiac
plasticity depends on a variety of factors, sometimes additive and occasionally counter-posed [12,14].
Therefore, new treatments in this field will necessarily be multidisciplinary and complementary or
synergic in a personalized patient approach. Control of alcohol-induced systemic damage seems
pivotal when approaching ACM [167,168]. Strategies combining a reduction of ethanol-dependent
inflicted damage as well as increasing local and systemic protective mechanisms of myocyte repair
will be necessary [9]. The development and application of new cardiomyokines (FGF21) [33,34,138]
isoform-specific ROCK inhibitors [92] and MicroRNAs [105,169] will probably be combined to improve
conventional therapeutic strategies such as control drinking [10,42], antioxidant supplementation [170],
and anti-inflammatory [92,171], anti-fibrotic [120] and anti-apoptotic [172] systemic treatments as well
as better use of stem-cell therapy [161] and heart transplantation [2,166] procedures.
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